Juvenescence raises $46M; Brainsway files for IPO; Life Biosciences raises

Anti-aging startup Juvenescence raises USD 46 Million

Juvenescence has bagged the USD 46 million in series B financing. The investment tees the anti-ageing startup to progress the multi-asset pipeline. Jim Mellon, a British billionaire biotech investor, created Juvenescence with early Medivation backer Greg Bailey and three others in 2017. Since then, the founders have utilised their capital and contacts to increase the growth of Juvenescence with USD 115 million in investment. Juvenescence hopes regarding figure to increase when it closes the next tranche of a forecast USD 100 million round.

Brainsway files for USD 30 Million Nasdaq IPO

Brainsway,the developer of magnetic device treatments for depression and obsessive-compulsive disorder, contemplates to file USD 30 million through an initial public offering on the Nasdaq. The Jerusalem-based company privately filed and the pricing terms were not disclosed. The company obtained a de novo clearance from the FDA for the use of its noninvasive, deep transcranial stimulation system in treating OCD through about 20-minute-long sessions.

Life Biosciences raises USD 50 Million

Life Biosciences has raised USD 50 million. The series B round will bolster the efforts of startup for building a portfolio of subsidiaries with assets targeting eight aging pathways. Life Biosciences is channelling capital into a bunch of startups that are working on different ways to attack age-related diseases for extending healthy life spans. The has led the company to found six subsidiaries that have access to shared lab space and artificial intelligence capabilities as well as to invest in Prana Biotechnology.